Moneycontrol Be a Pro
Get App
Last Updated : Jun 06, 2019 12:26 PM IST | Source: PTI

Alembic Pharma gets USFDA nod for Parkinson's disease treatment drugs

The approved products are therapeutically equivalent to the reference listed drug Sinemet CR tablets of Merck Sharp & Dohme Corp.

Alembic Pharmaceuticals on June 6 said it has received approval from the US health regulator for Carbidopa and Levodopa extended-release tablets, used for treatment of Parkinson's disease.

The approved products are therapeutically equivalent to the reference listed drug Sinemet CR tablets of Merck Sharp & Dohme Corp.

The company has received approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application Carbidopa and Levodopa extended-release tablets in the strengths of 2.5 mg/100 mg and 50mg/200 mg, Alembic said in a BSE filing.

Close

Quoting IQVIA sales data, the company said the two products had an estimated market size of USD 24 million for 12 months ended December 2018.

The company said it now has a total of 94 abbreviated new drug application (ANDA) approvals from the USFDA.

Shares of Alembic Pharmaceuticals were trading at Rs 511.05 apiece, down 0.08 percent, on the BSE.

Get access to India's fastest growing financial subscriptions service Moneycontrol Pro for as little as Rs 599 for first year. Use the code "GETPRO". Moneycontrol Pro offers you all the information you need for wealth creation including actionable investment ideas, independent research and insights & analysis For more information, check out the Moneycontrol website or mobile app.
First Published on Jun 6, 2019 12:16 pm
Loading...
Sections
Follow us on
Available On